Lion’s mane mushroom is one of the best selling brain supplements online, and one of the least tested. A 2025 review went looking for trials that measured thinking against a dummy pill. It found five, covering about 185 people in total (Review). In the most quoted of them, memory scores rose over 16 weeks, then dropped four weeks after people stopped (Trial). The biology is interesting. The proof in people is thin and mixed.
What Lion’s Mane Mushroom Is
Lion’s mane mushroom is a shaggy white fungus that grows on hardwood trees. Its scientific name is Hericium erinaceus. You can eat it, and in Japan it goes by the name yamabushitake (Trial). Most people now meet it as a capsule, a powder or an instant coffee.
Two groups of compounds carry the marketing. Hericenones sit in the fruiting body, the part that looks like a mushroom. Erinacines sit in the mycelium. That is the root-like web underneath, and it is grown in a lab rather than picked.
A 2026 lab study measured both kinds of product. One lab ran it to check its own testing method, and it put one mycelium product up against ten fruiting-body materials (Study). Erinacine A showed up only in the mycelium product. In every fruiting-body sample, the level was too low for the test to see (Study).
That matters more than it sounds. Two jars can both say lion’s mane and hold different chemistry. The label rarely tells you which one you bought.
The Nerve Growth Story
The hype has a real idea behind it. The usual explanation is nerve growth factor, a protein that helps nerve cells survive and repair. Researchers have long argued that these mushroom compounds push cells to make more of it. Even one trial team that found no sign of that effect still treats it as the working theory (Trial).
Erinacine A is the compound labs like most. One team built a 49-week Alzheimer’s trial around a mycelium product made to a set level of it (Trial).
That trial did look for change in the body, and it found a hint. Brain scans in the mushroom group shifted near the memory circuit. Researchers read that shift as healthier tissue. In the dummy group, a different measure moved the wrong way (Trial). Both were changes inside each group over time. The two groups never pulled apart from each other. The scans were a side check rather than the main test, so this is a hint to follow up, not proof.
Now the honest caveat. Most of this work happened in dishes and in animals. The newest round-up counted 26 studies, and 15 of them were lab work (Review). Only 10 involved people at all. A cell in a dish is not a person. Plenty of compounds look great on a bench and then do nothing in people.
What The Human Trials Show
An independent expert review counts seven trials where a coin flip decided who got the mushroom and who got a dummy pill (Review). It calls them small groups of people, treated for short periods, with mixed results on thinking. Here they are in order.
Mori 2009 is the trial everyone quotes. Thirty Japanese adults aged 50 to 80 took part, all with mild memory problems. They took 3 g of dried fruiting-body powder a day for 16 weeks (Trial). A coin flip decided who got the mushroom and who got a dummy tablet. Scores on a Japanese dementia screening test rose above the dummy group at weeks 8, 12 and 16.
Then comes the detail almost nobody quotes. Four weeks after people stopped taking it, their scores dropped again (Trial). That suggests the mushroom was propping the scores up rather than rebuilding anything. Take it away and the effect goes with it.
A later trial team read it the same way. They noted the gains were gone at the check four weeks after treatment ended (Trial). An independent expert review adds a second caveat. The dummy group’s scores crept up over the same period. That is what happens when people sit the same test again and again (Review).
Saitsu 2019 tested 31 healthy adults over 50 for 12 weeks. One test out of three improved. The same test also improved in the dummy group (Review).
Li 2020 is the longest trial anyone has run. It was a 49-week pilot in people with mild Alzheimer’s disease. A coin flip sorted 49 people into two groups, and 41 finished (Trial). They took about 1 g a day of mycelium rich in erinacine.
Scores on a common 30-point thinking test rose by about one and a half points in the treated group. That was a gain on their own starting point, not a win over the dummy capsule. The one clear gap between the groups was in daily tasks: cooking, cleaning and shopping (Trial). An independent review reads it the same way: better daily living, with no clear gain in thinking (Review). The mycelium maker paid for the study, supplied the product and paid five of the ten authors (Trial).
Docherty 2023 is the most careful healthy-adult trial in the set, and its results are humbling. A coin flip sorted 43 young adults, and 41 finished 28 days at 1.8 g a day (Trial). One hour after a single dose they were faster on a color-naming attention test, by about a twentieth of a second (Trial). The authors call that a one-task result in a small pilot, and say to read it with caution.
It was also the only same-day gain, and it came with a cost. On that same day, the mushroom group recalled fewer words than the dummy group. They also made more errors (Trial).
After 28 days of daily capsules, nothing had improved (Trial). On a delayed word-recall test, the dummy group got better over the month and the mushroom group stayed flat (Trial). With only 41 people, a flat result is weak evidence, not a closed case.
Surendran 2025 is the newest published trial and the smallest. Eighteen healthy adults took one 3 g dose of a fruiting-body extract of set strength. They sat tests 90 minutes later (Trial). Overall thinking and mood scores did not move.
Task by task, the results pointed both ways. Hand skill improved. Two attention tasks got worse, and the rest did not shift on lion’s mane (Trial). The extract was well described, so a cheap jar is not the excuse here (Trial). Two of the authors work for a company that sells lion’s mane drinks, and that company helped pay the publishing fee (Trial).
One more study is doing the rounds in 2026. A coin flip put 150 adults aged 40 to 75 into two groups for eight weeks. One group took a blend of fruiting body and mycelium, the other a dummy. Of the 109 counted in the results, 57 took the mushroom, and one attention task improved more than the dummy (Preprint). It is the largest trial yet. No outside experts have checked it, and a mushroom ingredient company paid for it. Staff there reviewed the numbers, though the paper says they could not change or drop any (Preprint). Treat it as a lead, not a result.
One gap is bigger than any single trial. Nobody has pooled these trials into one answer. The 2025 review tried and gave up, because the trials reported their numbers in ways too different to combine (Review). Add up the dummy-pill trials it found that measured thinking, and you get about 185 people. Count the two published since, and the total is still only a few hundred.
Compare that with our write-up of creatine for the brain. There, researchers had enough trials to pool into a single number. That is what a solid evidence base looks like. Lion’s mane is nowhere near it.
Where The Signal Is Better
Memory is the weakest part of the record. Mood and stress look a bit steadier. Only a bit, though, and the trials there are still tiny and short.
Nagano 2010 gave cookies to 30 Japanese women for four weeks. A coin flip decided whose cookies held mushroom, and 26 women were counted in the results (Trial). The mushroom cookies held 2 g of powdered fruiting body a day. Scores for low mood and menopause complaints fell. The dummy group’s scores fell by almost as much. On every total score the two groups ended up level, and sleep quality did not budge in either (Trial).
The authors were careful about their own findings. They suggested something other than nerve growth factor was at work, and they asked for more research in people (Trial).
In Docherty 2023, people on lion’s mane reported less stress after 28 days. The finding sat right on the edge, and it came from a simple slider scale. A tested stress questionnaire in the same trial showed nothing, and the authors said their findings should be read with caution (Trial).
The 2025 review is careful here too. It notes that only a few studies have looked at mood or sleep at all. It calls the benefit in patients limited, and the gains it does report temporary (Review). The 2025 single-dose trial found no mood benefit at all (Trial).
Keep one thing in mind. Mood you report yourself is the easiest thing in science to shift with a dummy pill. Small, short trials that ask people how they feel are where that effect shows up most.
What You Are Actually Buying
Most coverage stops before this point. Yet this is what decides whether any of the research above applies to your jar.
Start with the split. Fruiting body is the mushroom you would recognize. Mycelium is grown in a lab, usually on grain. The 2026 lab study found erinacine A only in the mycelium product it tested, and too little to measure in every fruiting-body sample (Study). One mycelium sample cannot settle the chemistry for the whole market. The paper does point to earlier work that found the same split (Study).
Then the numbers. That study measured marker compounds in seven finished products bought from local shops. It also tested raw materials handed over by the ingredient company that ran it (Study). Levels of the fruiting-body compounds ranged about 200 times over, top to bottom. One product held about 100 times more of a key compound than another (Study). In several samples the markers were too low for the lab to measure well (Study).
One compound did show up across the fruiting-body samples. It is ergosterol, a plain building block of fungi (Study). The single mycelium product held too little of it to measure. Ergosterol proves the jar holds mushroom. Nobody claims it does anything for the brain.
Read that paper with its own caveats attached. One lab ran it to test its own method, and an ingredient supplier that employs all four authors paid for it (Study). A company like that gains if the market looks like a mess. At least the finished products were bought in shops rather than donated.
Dose is no clearer. Across the human studies, daily amounts ran from about 1 g to 10 g, in powders, capsules, extracts, cookies and muffins (Review). No two trials used the same product. An independent expert review says plainly that dosing is not fully known (Review).
The practical version is short. Pick a fruiting-body extract if you want to match the trial people quote most. Look for testing by an outside lab. Treat any confident milligram claim on a label with suspicion.
Is Lion’s Mane Safe
Trials of long use describe it as easy to tolerate. Mild stomach upset, nausea or loose stools turned up in fewer than 1 in every 10 people, and rarely stopped anyone taking it (Review). The US LiverTox database gives it the lowest concern rating for liver injury, which means harm is unlikely (Review).
The problems are real but rare. At least one sudden allergic reaction to swallowed lion’s mane has been written up (Review). A 63-year-old man had severe lung failure after months of taking a lion’s mane extract. Lab tests confirmed that his immune cells reacted to the product (Case report). That is one case, not a rate. A mushroom allergy is still a genuine reason to skip this.
The 2025 review calls side effects rare, and often not reported at all (Review). The recorded list is short: stomach discomfort, headache, diarrhea, nausea, skin rash and allergic reactions. In the trial that tracked them best, mild stomach upset was about as common on the dummy tablet as on the mushroom (Review). One woman in the cookie trial was dropped from the results after reporting unusually frequent periods (Trial). The researchers did not link it to the mushroom.
The big gap is time. The longest human trial in that 2025 review ran about a year, and most lasted between one and 22 weeks (Review). The review searched only one database, so it is not a complete map. Even so, nobody appears to have tested five years of daily use. If you take medication or have a health condition, ask a clinician first.
Frequently Asked Questions
Does lion’s mane mushroom actually improve memory?
Not reliably, on the evidence so far. The trials are small and they disagree, and nobody has managed to pool them into a single answer (Review). The most quoted positive trial saw its gains fade four weeks after people stopped (Trial). In healthy young adults, 28 days of capsules produced no memory gain at all (Trial).
How long does lion’s mane take to work?
Nobody knows, because the trials do not agree. In one small pilot, a single dose sped up one attention test within an hour (Trial), while another single-dose trial found nothing overall (Trial). The trial that reported lasting gains ran 16 weeks, and those gains were gone a month after people stopped (Trial).
Is fruiting body or mycelium better?
The chemistry differs, but no trial has put them head to head. A 2026 lab study found erinacine A only in the mycelium product it tested (Study). The most quoted human trial used fruiting-body powder (Trial), while the longest one used mycelium rich in erinacine (Trial).
What is a proven lion’s mane dose?
There is not one. Daily doses across the human studies ran from about 1 g to 10 g, and no two trials used the same product (Review). An independent expert review states plainly that dosing is not fully known (Review).
Can you eat the mushroom instead of taking capsules?
It is an edible mushroom, so yes. The trials did not test meals, though. One baked 2 g of mushroom powder a day into cookies for four weeks (Trial). Another used one dose of extract equal to roughly 30 g of fresh mushroom (Trial). Neither one showed a convincing gain in thinking.
Key Takeaways
- The mechanism is interesting, and mostly untested in people. The newest review counted 26 studies, and 15 were lab work (Review).
- The human trials are tiny and they disagree. An expert review counts seven dummy-pill trials, each with a few dozen people and mixed results (Review).
- The benefit faded once people stopped. In the most quoted trial, scores rose over 16 weeks and dropped again four weeks after the capsules ended (Trial).
- No pooled answer exists. The 2025 review could not combine the trials, whose thinking tests covered about 185 people (Review).
- Products vary wildly. Marker compounds ranged about 200 times over across the samples tested (Study). Trial doses ran from 1 g to 10 g a day (Review).
- Short-term safety looks fine. Mild stomach complaints hit fewer than 1 in every 10 people, and the liver risk rating is low (Review). Nothing has been tested much past a year (Review).
Stay Curious, Stay Skeptical
Here is the verdict without the hedging. The biology is interesting. The proof in people is not there. Lion’s mane is cheap, and over a few months it looks low risk. Trying it is a fair experiment if you enjoy running one. Just do not build a memory plan on it, and do not spend much.
The better move is to check the record yourself. Every study behind this article is linked above. Read the fade in the Mori trial, the flat result in Docherty, and the limits section of the 2025 review. They tell a more useful story than any product page.
The evidence here is still being built. It is worth watching, and not yet worth believing.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Bio-Hacking.Blog 
Leave a comment